To the Editor,

We recently read with great interest the article by Yilmaz and Uzun,1 describing the efficacy and safety of low dose thrombolytic therapy (TT) in patients with acute submassive pulmonary embolism (PE). We would like to emphasize a few points in light of current evidence.

PE is one of the most frequently reported thrombotic complications,2 and is more prevalent in critically ill patients with coronavirus disease 2019 (COVID-19). Thirty-day results have shown that patients with COVID-19 and PE received no significant benefit from empirically administered prophylactic anticoagulants at moderate doses against venous thrombosis or mortality.3 In submassive …